Xilio Therapeutics Inc
NASDAQ:XLO
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Jervois Global Ltd
ASX:JRV
|
AU |
|
Highwoods Properties Inc
NYSE:HIW
|
US |
|
Sportsfield Co Ltd
TSE:7080
|
JP |
|
Dhani Services Ltd
BSE:532960
|
IN |
|
R
|
Rockland Resources Ltd
CNSX:RKL
|
CA |
|
A
|
Anhui Expressway Co Ltd
SSE:600012
|
CN |
|
A
|
ACP Energy PLC
LSE:ACPE
|
UK |
|
Country Garden Holdings Co Ltd
HKEX:2007
|
CN |
|
Renesas Electronics Corp
TSE:6723
|
JP |
|
T
|
TXC Corp
TWSE:3042
|
TW |
|
GoTo Gojek Tokopedia PT Tbk
IDX:GOTO
|
ID |
|
TongHwa Corp
TWSE:1418
|
TW |
|
Bunge Ltd
NYSE:BG
|
US |
|
R
|
Rallybio Corp
NASDAQ:RLYB
|
US |
|
Hexpol AB
STO:HPOL B
|
SE |
|
Appswarm Inc
OTC:SWRM
|
US |
|
Betmakers Technology Group Ltd
ASX:BET
|
AU |
|
Chipsea Technologies Shenzhen Corp Ltd
SSE:688595
|
CN |
|
R
|
RRIL Ltd
BSE:531307
|
IN |
|
V
|
Vipul Organics Ltd
BSE:530627
|
IN |
|
Nokia Oyj
OMXH:NOKIA
|
FI |
|
Exicure Inc
NASDAQ:XCUR
|
US |
|
D
|
Dida Inc
HKEX:2559
|
CN |
|
P
|
Philippine Realty and Holdings Corp
XPHS:RLT
|
PH |
Xilio Therapeutics Inc
Other
Xilio Therapeutics Inc
Other Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Other | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
X
|
Xilio Therapeutics Inc
NASDAQ:XLO
|
Other
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Abbvie Inc
NYSE:ABBV
|
Other
$45m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Other
-$440m
|
CAGR 3-Years
-37%
|
CAGR 5-Years
-26%
|
CAGR 10-Years
20%
|
|
|
Amgen Inc
NASDAQ:AMGN
|
Other
-$10.9B
|
CAGR 3-Years
-372%
|
CAGR 5-Years
-161%
|
CAGR 10-Years
-34%
|
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Other
-$366.2m
|
CAGR 3-Years
-30%
|
CAGR 5-Years
-13%
|
CAGR 10-Years
N/A
|
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Other
-$542.4m
|
CAGR 3-Years
-7%
|
CAGR 5-Years
4%
|
CAGR 10-Years
-5%
|
|
Xilio Therapeutics Inc
Glance View
Xilio Therapeutics, Inc. operates as a biotechnology company. The company is headquartered in Waltham, Massachusetts and currently employs 74 full-time employees. The company went IPO on 2021-10-22. The firm has built its geographically precise solutions (GPS) platform to rapidly engineer molecules, including cytokines and other biologics. The Company’s most advanced product candidates are in clinical development. Its XTX101 is a clinical-stage, tumor-selective anti-CTLA-4 mAb, which is designed to improve upon the therapeutic index of existing anti-CTLA-4 therapies by localizing its activity in the TME. The company initiated a Phase I/II trial to evaluate XTX101 in patients with advanced solid tumors, and enrollment is ongoing. XTX202 is an engineered form of IL-2, which is masked with a protein domain to prevent binding activity until the protein domain is cleaved off by TME-associated proteases. The company initiated a Phase I/II trial to evaluate XTX202 in patients with solid tumors.
